State Street SPDR S&P Bio... (XBI)

Several hated assets could benefit if consensus starts cracking

<p>Moderna's 177% pop on a Phase 3 cancer-vaccine win rippled far beyond one stock.</p>

A bond market selloff has pressured 60/40 investment portfolios, which have returned 8% on average this year compared with 13% for the S&P 500. Investors can look to healthcare stocks for relief.

Moderna’s breakthrough highlights a broader transformation, as AI accelerates the clinical development of therapies at a pace that would have seemed unimaginable a few years ago.

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.